Kevin Puylaert
Known title: Chief Sales OfficerCIK: 0002119354
Associated companies
Transaction History
| SOPH | ▼ Sell | Open Market | 47 | $236 | 7/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 31 | $158 | 7/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 138 | $693 | 7/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 33 | $150 | 5/19/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 33 | $168 | 4/20/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 548 | $3K | 4/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 46 | $224 | 4/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 30 | $145 | 4/6/2026 | View on chart |
| SOPH | ▲ Buy | Grant | 56,468 | $0 | 4/2/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 3 | $14 | 3/31/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 33 | $157 | 3/19/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum
Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum. Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.